Rosiglitazone combined with insulin preserves islet β cell function in adult-onset latent autoimmune diabetes (LADA)

Diabetes/Metabolism Research and Reviews

Volumn 21, Issue 2, 2005, Pages 203-208

  Zhou, Zhiguang ^a   Li, Xia ^a   Huang, Gan ^a   Peng, Jian ^a   Yang, Lin ^a   Yan, Xiang ^a   Wang, Jianping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Insulin; Islet cell function; Latent autoimmune diabetes in adults; Therapy; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; C PEPTIDE; GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; ROSIGLITAZONE;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; KIDNEY DYSFUNCTION; LATENT AUTOIMMUNE DIABETES; LIVER DYSFUNCTION; MALE; MATURITY ONSET DIABETES MELLITUS; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

AGE OF ONSET; BODY MASS INDEX; C-PEPTIDE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 16344390566     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.503     Document Type: Article

References (42)

1. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42: 359-362.
2. Zimmet PZ, Tuomi T, Mackay IR, et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994; 11: 299-303.
3. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of adults): definition, characterization, and potential prevention. Diabetes Care 2001; 24: 1460-1467.
4. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive β-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996; 45: 622-626.
5. Kobayashi T, Maruyama T, Shimada A, et al. Insulin intervention to preserve cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann NY Acad Sci 2002; 958: 117-130.
6. Di Mario U, Dotta F. Modulation of antigen expression in relation to intervention strategies in type 1 diabetes. Diabetes Metab Rev 1993; 9: 245-249.
7. Cabrera-Rode E, Perich P, Diaz-Horta O, et al. Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment. Autoimmunity 2002; 35: 469-474.
8. Shimada A, Imazu Y, Morinaga S, et al. T-cell insulitis found in anti-GAD65+ diabetes with residual β-cell function. Diabetes Care 1999; 22: 615-617.
9. Carlsson A, Sundkvist G, Groop L, Tuomi T. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab 2000; 85: 76-80.
10. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003; 63: 1373-1405.
11. Buckingham RE, Al-Barazanji KA, Toseland CD, et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998; 47: 1326-1334.
12. Jia DM, Otsuki M. Troglitazone stimulates pancreatic growth in normal rats. Pancreas 2002; 24: 303-312.
13. Beales PE, Liddi R, Giorgini AE, et al. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. Eur J Pharmacol 1998; 357: 221-225.
14. Beales PE, Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. Diabetes Metab Res Rev 2002; 18: 114-117.
15. World Health Organization. Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, Switzerland; World Health Organization; 1999.
16. Petersen JS, Hejnaes KR, Moody A, et al. Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay. Diabetes 1994; 43: 459-467.
17. Grubin CE, Daniels T, Toivola B, et al. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994; 37: 344-350.
18. Li X, Zhou Z, Huang G, Yan X, Yang L, Hu B. Glutamic acid decarboxylase 65 (GAD65) antibody titers identify two subtypes of latent autoimmune diabetes in adults (LADA). Chin J Intern Med (Chinese) 2003; 42: 7-10.
19. Ido Y, Vindigni A, Chang K, et al. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 1997; 277: 563-566.
20. Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med 2000; 17: 181-189.
21. Wahren J, Ekberg K, Samnegard B, Johansson BL. C-peptide: a new potential in the treatment of diabetic nephropathy. Curr Diab Rep 2001; 1: 261-266.
22. Ekberg K, Brismar T, Johansson BL, Jonsson B, Lindstrom P, Wahren J. Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes 2003; 52: 536-541.
23. Barnett AH. Insulin-sensitizing agents-thiazolidinediones (glitazones). Curr Med Res Opin 2002; 18(Suppl 1): S31-S39.
24. Reasner CA. Where thiazolidinediones will fit. Diabetes Metab Res Rev 2002; 18(Suppl 2): S30-S35.
25. Gottsater A, Landin-Olsson M, Lernmark A, Fernlund P, Sundkvist G, Hagopian WA. Glutamate decarboxylase antibody levels predict rate of beta-cell decline in adult-onset diabetes. Diabetes Res Clin Pract 1995; 27: 133-140.
26. Borg H, Gottsater A, Landin-Olsson M, Fernlund P, Sundkvist G. High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 2001; 86: 3032-3038.
27. Lohmann T, Kellner K, Verlohren HJ, et al. Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia 2001; 44: 1005-1010.
28. Yang XY, Wang LH, Mihalic K, et al. Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands. J Biol Chem 2002; 277: 3973-3978.
29. Cunard R, Ricote M, DiCampli D, et al. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol 2002; 168: 2795-2802.
30. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000; 164: 1364-1371.
31. Yang XY, Wang LH, Chen T, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 2000; 275: 4541-4544.
32. Harris SG, Phipps RP. The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis. Eur J Immunol 2001; 31: 1098-1105.
33. Wang P, Anderson PO, Chen S, Paulsson KM, Sjogren HO, Li S. Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. Int Immunopharmacol 2001; 1: 803-812.
34. Saubermann LJ, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis 2002; 8: 330-339.
35. Katayama K, Wada K, Nakajima A, et al. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 2003; 124: 1315-1324.
36. Wada K, Nakajima A, Blumberg RS. PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease. Trends Mol Med 2001; 7: 329-331.
37. Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999; 104: 383-389.
38. Niino M, Iwabuchi K, Kikuchi S, et al. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J Neuroimmunol 2001; 116: 40-48.
39. Feinstein DL, Galea E, Gavrilyuk V, et al. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 2002; 51: 694-702.
40. Diab A, Deng C, Smith JD, et al. Peroxisome proliferators activated receptor gamma agonist 15- deoxy - Delta (12, 14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002; 168: 2508-2515.
41. Augstein P, Dunger A, Heinke P, et al. Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells. Biochem Biophys Res Commun 2003; 304: 378-384.
42. Dubois M, Pattou F, Kerr-Conte J, et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000; 43: 1165-1169.